Literature DB >> 6794308

Therapeutic effect of aspirin in sickle cell anaemia.

N O Osamo, D P Photiades, A A Famodu.   

Abstract

This work was carried out to demonstrate the possibility of beneficial therapeutic effects of aspirin in sickle cell anaemia patients. Two groups of 50 patients each, with haemoglobin genotype SS were studied, one group receiving soluble aspirin daily for 6 weeks, while the other was used as a control. There was evidence of increase in oxygen affinity, in haemoglobin levels, and in the life span of RBC, probably due to acetylation of HbS.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6794308     DOI: 10.1159/000207105

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  13 in total

1.  Role of the coagulation system in the pathogenesis of sickle cell disease.

Authors:  Md Nasimuzzaman; Punam Malik
Journal:  Blood Adv       Date:  2019-10-22

Review 2.  Prospects for primary stroke prevention in children with sickle cell anaemia.

Authors:  Lori C Jordan; James F Casella; Michael R DeBaun
Journal:  Br J Haematol       Date:  2012-01-09       Impact factor: 6.998

Review 3.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

4.  Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice.

Authors:  Paritha I Arumugam; Eric S Mullins; Shiva Kumar Shanmukhappa; Brett P Monia; Anastacia Loberg; Maureen A Shaw; Tilat Rizvi; Janaka Wansapura; Jay L Degen; Punam Malik
Journal:  Blood       Date:  2015-08-18       Impact factor: 22.113

Review 5.  Interplay between coagulation and vascular inflammation in sickle cell disease.

Authors:  Erica Sparkenbaugh; Rafal Pawlinski
Journal:  Br J Haematol       Date:  2013-04-18       Impact factor: 6.998

6.  Moyamoya syndrome in sickle cell anaemia: a cause of recurrent stroke.

Authors:  Deanne Soares; Richard Bullock; Susanna Ali
Journal:  BMJ Case Rep       Date:  2014-09-01

Review 7.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

8.  A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease.

Authors:  Payal C Desai; Julia E Brittain; Susan K Jones; Adam McDonald; Douglas R Wilson; Rosalie Dominik; Nigel S Key; Leslie V Parise; Kenneth I Ataga
Journal:  Thromb Res       Date:  2013-08-08       Impact factor: 3.944

9.  Advances in new drug therapies for the management of sickle cell disease.

Authors:  Kenneth I Ataga; Payal C Desai
Journal:  Expert Opin Orphan Drugs       Date:  2018-05-14       Impact factor: 0.694

10.  A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.

Authors:  Joseph A Jakubowski; Chunmei Zhou; David S Small; Kenneth J Winters; D Richard Lachno; Andrew L Frelinger; Jo Howard; Timothy G Mant; Stipo Jurcevic; Christopher D Payne
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.